Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 20/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL105084 | 0.87 | TTK (0.73) | TTK | |
| SCHEMBL9937922 | 0.86 | TTK (0.76) | TTK | |
| SCHEMBL16966389 | 0.86 | TTK (0.74) | TTK | |
| SCHEMBL2370850 | 0.86 | TTK (1.00) | TTK | |
| SCHEMBL9935513 | 0.86 | TTK (0.76) | TTK | |
| SCHEMBL104317 | 0.85 | TTK (1.00) | TTK | |
| SCHEMBL16966384 | 0.85 | TTK (0.70) | TTK | |
| SCHEMBL9935834 | 0.85 | TTK (0.85) | TTK | |
| SCHEMBL16966382 | 0.85 | TTK (0.70) | TTK | |
| SCHEMBL16966351 | 0.84 | TTK (0.69) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | claimed |
| EP-2547680-B1 | IMIDAZOPYRAZINES | BAYER IP GMBH (DE) | 2015-08-05 | — | — | EP | claimed |
| US-20130195848-A1 | IMIDAZOPYRAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| EP-2547680-A1 | IMIDAZOPYRAZINES | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | claimed |
| WO-2011113862-A1 | IMIDAZOPYRAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-22 | — | — | WO | claimed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9199999-B2 | Substituted imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2547680-B1 | IMIDAZOPYRAZINES | BAYER IP GMBH (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-20130210815-A1 | SUBSTITUTED IMIDAZOPYRAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130195848-A1 | IMIDAZOPYRAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-01 | — | — | US | disclosed |
| EP-2547680-A1 | IMIDAZOPYRAZINES | Bayer Intellectual Property GmbH (DE) | 2013-01-23 | — | — | EP | disclosed |
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2011113862-A1 | IMIDAZOPYRAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011113862-A1 | IMIDAZOPYRAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011013729-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | オンコセラピー・サイエンス株式会社 (JP) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TTK 6/4885 |
| US-20130210815-A1 | SUBSTITUTED IMIDAZOPYRAZINES | CYP3A5, CYP3A43, HRH2 | TTK 4616/4885 |
| US-20130195848-A1 | IMIDAZOPYRAZINES | F12, C1R, XDH | TTK 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.